Accumulate Opto Circuits; tgt of Rs 330: Unicon Investment

12058 Investors following Opto Circuits. Share this News with them.

0

Like this story, share it with millions of investors on M3

Accumulate Opto Circuits; tgt of Rs 330: Unicon Investment

Unicon Investment is bullish on Opto Circuits India and has recommended accumulate rating on the stock with a target of Rs 330 in its July 28, 2011 research report.

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Accumulate Bank of India; target Rs 434: Angel Broking Buy Bank of Baroda; target of Rs 1086: LKP Buy GAIL India; target of Rs 496: PINC Research ALSO READ See previous views by Unicon Investment See what other Experts & Brokerages are saying about Opto Circuits See messages about Opto Circuits Opto Circuits BSE | NSE 30/05/12 Are Mutual Funds betting on Opto Circuits?

Unicon Investment is bullish on Opto Circuits India and has recommended accumulate rating on the stock with a target of Rs 330 in its July 28, 2011 research report.

"Opto Circuits posted a good set of numbers for Q1FY12. Result was almost inline with our expectation, except the revenue that showed a growth of 78.4% (verses our estimate of 85% growth) form the same period last year. However there was a concern over its EBITDA margin that contracted by around 2425 bps. Overall the company delivered a good volume growth which helped it net profit grow by 40%."

"Opto Circuits reported a top line growth of 78.4% YoY with the total revenue coming in at INR 5208 mn. The growth in the revenue was backed by the significant upside in the revenues contributed by International healthcare segment. Around 98% of the total revenue comes from its international business which showed an upside of 80% YoY. However, despite the significant growth in the revenue, there was a huge contraction of 2425 bps in the EBITDA margin that came in at 27.5%. Employee cost and other expenses almost doubled as compared to the same period last year taking a toll on the margins. EBITDA stood at INR 1432 mn and showed a growth of 47.5% YoY which was mainly in line with our expectation.Net profit was well in line with our estimate and came in at INR 1164 mn with the upside of 40%. Opto earned large contracts during the quarter across the various product categories in Columbia, Spain, US and India. This is expected to give a ramp up to the revenue of the company in the coming quarters of FY12. It launched a new web based ishop for online shopping of all Cardiac Science products which would give a boost to the revenue generation from the segment."

"After restructuring of its Cardiac Science business we see there has been a significant jump in the revenue. Launch of products like Taxcor Plus, Dior, Freeway and Magical have given a boost to the healthcare business of the company. Thus going forward we see a high value growth coming in from these products and expect the company to register 25-30% revenue upside in next 2-3 yrs. Currently, the stock is trading at 11.5x its FY12E earnings and we expect it to continue its current growth trend in the coming quarters. Thus we maintain our ACCUMULATE rating on the stock with price target of INR 330," says Unicon Investment research report. 

Institutional holding more than 40% in Indian cos

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click on the attachment